Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading on Thursday. $114.40 million flowed into the stock on the tick-up and $152.57 million flowed out of the stock on the tick-down, for a money net flow of $38.17 million out of the stock. Of all companies tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.61 for the day and closed at $45.51
PFE has been the topic of several analyst reports. Cantor Fitzgerald set a $45.00 price target on Pfizer and gave the company a “buy” rating in a report on Thursday, October 4th. Morgan Stanley set a $45.00 price target on Pfizer and gave the company a “buy” rating in a report on Wednesday, August 29th. Goldman Sachs Group reiterated a “neutral” rating and set a $45.00 price target on shares of Pfizer in a report on Tuesday, October 30th. Independent Research set a $48.00 price target on Pfizer and gave the company a “neutral” rating in a report on Thursday, October 4th. Finally, Credit Suisse Group set a $40.00 price target on Pfizer and gave the company a “hold” rating in a report on Thursday, September 6th. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $43.27.
The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.15. The stock has a market cap of $270.91 billion, a price-to-earnings ratio of 15.27, a P/E/G ratio of 2.27 and a beta of 0.88.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be given a $0.34 dividend. The ex-dividend date is Thursday, November 8th. This represents a $1.36 annualized dividend and a yield of 2.94%. Pfizer’s dividend payout ratio (DPR) is currently 51.32%.
In other news, major shareholder Pfizer Inc bought 55,556 shares of Pfizer stock in a transaction that occurred on Monday, October 15th. The stock was purchased at an average cost of $18.00 per share, with a total value of $1,000,008.00. Following the completion of the transaction, the insider now directly owns 21,976,484 shares in the company, valued at $395,576,712. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by company insiders.
Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Pfizer by 1.5% during the third quarter. Vanguard Group Inc. now owns 441,792,969 shares of the biopharmaceutical company’s stock valued at $19,469,816,000 after acquiring an additional 6,620,749 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Pfizer by 3.7% during the third quarter. Bank of New York Mellon Corp now owns 70,231,649 shares of the biopharmaceutical company’s stock valued at $3,095,110,000 after acquiring an additional 2,497,736 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in shares of Pfizer by 0.3% during the second quarter. Massachusetts Financial Services Co. MA now owns 61,881,280 shares of the biopharmaceutical company’s stock valued at $2,245,053,000 after acquiring an additional 160,730 shares during the period. Morgan Stanley lifted its holdings in shares of Pfizer by 2.1% during the third quarter. Morgan Stanley now owns 55,493,846 shares of the biopharmaceutical company’s stock valued at $2,445,614,000 after acquiring an additional 1,126,612 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Pfizer by 15.0% during the second quarter. Dimensional Fund Advisors LP now owns 54,233,658 shares of the biopharmaceutical company’s stock valued at $1,967,651,000 after acquiring an additional 7,059,171 shares during the period. 68.64% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece was published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.com-unik.info/2018/12/01/traders-sell-pfizer-pfe-on-strength-pfe.html.
Pfizer Company Profile (NYSE:PFE)
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Further Reading: Asset Allocation and Your Retirement
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.